INTRODUCTION
Non-small cell lung cancer (NSCLC) accounts for nearly 85% of lung cancers; and, despite advances in treatment, the 5-year survival rate remains less than 20%. 1 Erlotinib is an epidermal growth factor receptor (EGFR) oral tyrosine kinase inhibitor (TKI) that was first approved in 2004 for the treatment of advanced NSCLC (irrespective of histology or EGFR mutation status) after failure of at least 1 chemotherapy regimen. This was based on the National Cancer Institute of Canada Clinical Trials Group study BR.21, which was undertaken before EGFR mutations were established as a predictive factor. 2 A maintenance study (Sequential Tarceva in Unresectable NSCLC [SATURN] ) examined the use of erlotinib (Tarceva; Genentech, South San Francisco, Calif) versus placebo as maintenance in patients with nonprogressive disease after first-line platinum doublet chemotherapy. 3 Progression-free survival (PFS) was significantly prolonged, favoring adenocarcinoma histology, EGFR expression, never smokers, Asians, and women. 3 Erlotinib was approved for the first-line treatment of metastatic nonsquamous NSCLC with a known, active, sensitizing EGFR mutation. 4 MET (mesenchymal-epidermal transition factor [c-MET]; hepatocyte growth factor receptor [HGFR] ) is the tyrosine kinase receptor for hepatocyte growth factor (HGF) and mediates procancer functions, including growth, invasion, metastasis, and epithelial-to-mesenchymal transition (EMT). 5 Membrane overexpression, gene amplification, mutation, or alternative splicing resulting in exon 14 skipping are observed in various tumors. [5] [6] [7] A critical role for MET deregulation in the pathophysiology of NSCLC is established in human cell lines and patient tumor tissues 8 as well as in animal models. 9 MET amplification is also a mechanism of acquired resistance to EGFR inhibitors by activating erb-b2 receptor tyrosine kinase 3 (ERBB3) (human epidermal growth factor receptor 3 [HER3]) signaling to phosphatidylinositol 3-kinase (PI3K)/serine/ threonine kinase (AKT [protein kinase B]). [10] [11] [12] [13] MET inhibition produces durable responses in MET-related malignancies, 6, 7 whereas combined treatment with EGFR and MET inhibitors reverses the conferred resistance to EGFR inhibitors and restores antitumor efficacy. [12] [13] [14] [15] We previously demonstrated reciprocal cross-activation between MET and wild-type (WT) EGFR in NSCLC, involving downstream release of EGFR ligands initiated by HGF treatment in NSCLC cells. 16, 17 EGFR activated by its ligands, in turn, causes a prolonged HGFindependent activation of MET. 16, 17 Blocking EGFR and HGF together could reduce EGFR signaling while simultaneously inhibiting both the ligand-dependent and ligand-independent activation of MET. 16 This combination might benefit both patients with EGFR-mutant and those with EGFR WT tumors.
Rilotumumab (AMG 102) is a fully humanized monoclonal antibody (immunoglobulin G2 [IgG2]) that neutralizes HGF, thus preventing MET activation. 18 It can produce tumor regression in animal models, 19 and its administration in humans was deemed safe up to the highest dose tested (20 mg/kg) as monotherapy. 20 We used rilotumumab to conduct a phase 1/2 combination study of erlotinib in patients with pretreated, metastatic NSCLC.
MATERIALS AND METHODS

Eligibility Criteria
Patients aged 18 years with the ability to provide written informed consent who had recurrent or progressive, advanced-stage NSCLC were enrolled. They were required to have received treatment with at least 1 and a maximum of 2 prior chemotherapy regimens. Those who had received prior erlotinib, other EGFR TKIs, or antibodies targeting EGFR were not included. Eligible patients had to meet specific safety and laboratory criteria, and patients with treated brain metastasis were allowed. The University of Pittsburgh Institutional Review Board approval was obtained for all study procedures and for informed consent documents in accordance with the Declaration of Helsinki.
Study Design and Statistical Methods
This was a phase 1/2 trial to evaluate the safety, recommended phase 2 dose (RP2D), and efficacy of rilotumumab in combination with erlotinib. Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) were adopted for response assessment. Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE, version 4).
For the phase 1 part of the trial, we adopted a deescalation design. If dose de-escalation was needed, then a dose reduction according to the Narayana k-in-a-row design would follow, setting the RP2D as the maximum below the dose associated with a 25% dose-limiting toxicity (DLT) rate. 21 Rilotumumab was started at an initial dose of 15 mg/kg (dose level 0) and was planned to be de-escalated to 7.5 mg/kg (dose level 21) or 5 mg/kg (dose level 22) in case of DLT; whereas patients received oral erlotinib at a dose of 150 mg daily. DLT criteria were specified in the study protocol. The study planned to enroll from 8 to 16 patients in phase 1. In the absence of DLT among the first 8 patients, dose level 0 would be declared the RP2D. The goal of the phase 2 part was to test whether the disease control rate (DCR) of 50% for erlotinib (as reported in the BR.21 trial among patients who were unselected for EGFR mutation 22 ) could be improved by adding rilotumumab; an improvement to a DCR of 70% was targeted (Type I error 5 Type II error 5 10%; power 5 90%). Phase 2 adopted a Simon 2-stage design, in which 21 patients received treatment treated at the RP2D in stage 1, and 24 received treatment in stage 2, for a total of 45 response-evaluable patients. Secondary objectives included estimates of overall survival (OS) and progression-free survival (PFS) and exploratory correlations with patient tissue and serum.
Clinical response trends (complete remission, partial remission, stable disease, and progressive disease) were assessed by histology and mutation status using the Cochran-Armitage trend test. OS and PFS were estimated using the Kaplan-Meier method. Enzyme-linked immunosorbent assay (ELISA) results from 10 HGF-EGFR pathway markers were tested for their association with PFS. Analyses proceeded with hierarchical agglomeration clustering and by estimating proportional-hazards regression on PFS. Adjustment of P values used the method of Benjamini and Hochberg. 23 
Drug Administration
Patients received intravenous rilotumumab once every 3 weeks (1 treatment cycle) at a starting dose of 15 mg/kg. Intrapatient dose modifications were not allowed: a dose was either received or held. Patients received oral erlotinib 150 mg. Dose modification criteria to 100 mg and 50 mg were provided.
Biomarker Analyses
EGFR and Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation status was determined using Clinical Laboratory Improvement Amendments-approved protocols, which sequenced EGFR exons 19 and 20 and KRAS exons 12, 13, and 61. Molecular testing either was done at the University of Pittsburgh Molecular Pathology core facility or was performed by the hospital where the NSCLC diagnosis was first made. DNA sequencing was successful in 35 patients for EGFR and in 34 patients for KRAS. In other patients, DNA sequencing was inconclusive or sufficient tumor material was not available. Baseline blood samples were also available from 35 enrolled patients. Blood was processed for isolation of plasma, immediately aliquoted, frozen, and stored at 2808C.
Post-treatment blood samples also were available for a subset of 30 patients at cycle 2 and for 9 patients at cycles 3, 5, and 7. Individual ELISAs for HGF (Quantikine ELISA; R&D Systems, Minneapolis, Minn), neuregulin 1 (NRG-1) (Abcam, Cambridge, UK), transforming growth factora (TGF-a) (Quantkine ELISA; R&D Systems), heparin binding-EGF (HB-EGF) (DuoSet ELISA; R&D Systems), amphiregulin (AREG) (DuoSet ELISA; R&D Systems), vascular endothelial growth factor (VEGF) (Quantikine ELISA; R&D Systems), b-estradiol (Cayman Chemical, Ann Arbor, Mich), and soluble MET (ThermoFisher Scientific, Waltham, Mass) were used to quantify each plasma analyte according to the manufacturer's instructions. In addition interleukin 6 (IL6) and IL8 were analyzed together as a part of a multiplex Meso Scale Discovery assay (Meso Scale Diagnostics, Rockville, Md). Assays were performed in duplicate, and concentrations between the replicates varied by less than 10%. Mean values were used for analysis. We were unable to evaluate an association of MET protein expression in the tumors with outcome because of a lack of sufficient tumor tissue.
RESULTS
Patient Demographics and Disease Characteristics
In total, 49 patients were screened and enrolled. Of these, 4 patients did not complete the required milestone for response evaluation, leaving 45 patients evaluable for efficacy analysis (Table 1) . Thirty-two patients had adenocarcinoma histology, and 13 had squamous histology. Two patients had confirmed EGFR mutations, and 33 had WT EGFR. Eight patients had KRAS mutations. Ten patients had unknown EGFR mutation status, and 11 patients had unknown KRAS mutation status. Enrolled patients had received a median of 2 previous chemotherapy regimens.
Safety and Drug Administration
Phase 1 included 8 patients; and, in the absence of DLT, the RP2D was set at dose level 0 (rilotumumab 15 mg/kg every 3 weeks plus erlotinib 150 mg daily). These patients were included in phase 2 in accordance with the study's original design. Rilotumumab combined with erlotinib was generally well tolerated. Table 2 presents the adverse events that were considered related to the study regimen by category and severity. The median number of study treatment cycles administered was 4 (range, from 1 to 18 cycles).
Efficacy
The DCR reached 60% (90% confidence interval [CI], 47%-71%), and 4 patients achieved a confirmed partial response (8.8%; 90% CI, 0.4%-18.4%). Partial responses ranged from 2 to 4 months in duration. Stable disease and objective responses were observed irrespective of NSCLC histology or of EGFR or KRAS mutation status. Median PFS for all patients reached 2.6 months (90% CI, 1.4-3.3 months) and median OS was 6.6 months (90% CI, 5.6-8.9 months), with a 1-year survival probability of 0.32 (90% CI, 0.22-0.46) (Fig. 1A,B) . PFS in the molecularly confirmed EGFR WT subset was 2.6 months (90% CI, 1.4-2.7 months), and OS in this subset was 7.0 months (90% CI, 5.6-13.4 months) ( Fig. 2A,B) .
Longer PFS Among Patients With High Baseline Plasma NRG-1 and Low AREG, TGF-a, and IL6
Next, we examined 10 circulating biomarkers that were selected for their association with the EGFR and MET (29) 4 (9) 5 (11) 0 (0) Hepatitis elevated ALT/AST/AP/GGT 18 (40) 10 (22) 5 (11) 3 (7) 0 (0) Oral mucositis 5 (11)
Abbreviations: ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; GGT, g-glutamyltransferase. pathways for correlation with outcomes among the 35 trial participants who had baseline blood samples available. Demographics of this subset revealed no significant differences compared with the total patient group. The biomarkers measured included 4 EGFR/HER ligands: AREG, HB-EGF, TGF-a, and NRG-1. We also measured plasma levels of HGF and soluble MET as well as 4 factors known to be regulated by HGF: VEGF, bestradiol, IL6, and IL8. We examined correlations among the markers and observed that TGF-a was highly correlated with both HGF (q 5 0.60; P 5 .0002; false discovery rate, 0.009) and IL8 (q 5 0.45; P 5 .0082; false discovery rate, 0.184). NRG-1 was negatively correlated with 2 of the other HER ligands (AREG, q 5 20.35; TGF-a, q 5 20.34; P < .05). All patients had detectable levels of soluble MET and HGF in plasma. At cycle 2, the HGF level increased from a median baseline of 2184 pg/mL to a median of Figure 1 . For all patients, (A) median progression-free survival was 2.6 months (90% confidence interval [CI], 1.4-3.3 months), and (B) median overall survival was 6.6 months (90% CI, 5.6-8.9 months). Gray bands indicate 90% CIs for survival probability. 5027 pg/mL. Among 10 patients who had measurements throughout 7 cycles, a nonlinear increase that plateaued over time was observed (Supporting Fig. 1 ; see online supporting information). The elevation in HGF was consistent with a pharmacodynamic effect of rilotumumab, as demonstrated by previous clinical results. 24 Also consistent with previous results, HGF baseline plasma levels and changes in HGF did not correlate with treatment response. 24 Neither baseline levels nor changes in soluble MET were correlated with response to rilotumumab combined with erlotinib, also consistent with other clinical studies. 24 Baseline levels of AREG, IL6, NRG-1, and TGF-a were significantly associated with PFS, with the false discovery rate was set at <10%. High NRG-1 levels were associated with longer PFS (hazard ratio [HR], 0.41; 95% CI, 0.19-0.87); whereas high levels of AREG (HR, 2.14; 95% CI, 1.48-3.08), TGF-a (HR, 1.77, 95% CI, 1.01-3.11), and IL6 (HR, 1.29; 95% CI, 1.09-1.53) were associated with more rapid progression ( Table 4) . None of these markers changed appreciably after treatment, over up to 7 treatment cycles (results not shown). Baseline levels or changes over time in levels of VEGF, IL8, HB-EGF, and b-estradiol were not significantly associated with PFS or other outcome measures (not shown).
Clustering of baseline markers in a heat map sorted by PFS for each patient also indicated that higher NRG-1 levels clustered with better PFS (Fig. 3) . Two distinct clusters were identified: 1 was based on NRG-1 status, whereas all of the other markers identified a second cluster, confirming the importance of NRG-1 in association with response to this drug combination. The heat map illustrates that patients who had a PFS 4 months also had lower plasma levels of AREG, TGF-a, and VEGF. Lower levels of IL6, IL8, and HB-EGF also were clustered with longer PFS, whereas HGF and soluble MET levels did not have this relation.
DISCUSSION
This is a first-in-human study to combine an EGFRtargeted therapy with an HGF-neutralizing antibody in heavily pretreated, unselected patients with advanced NSCLC. The choice of this therapeutic combination was based on preclinical data indicating c-Met as either de novo up-regulated in NSCLC 5, 8, 9, 13 or as an escape mechanism to EGFR inhibition, [10] [11] [12] 14 with a possible synergistic effect, 15 and on observations of signaling interactions between EGFR and c-Met. 16, 17 The combination proved to be tolerable, with no DLTs observed during phase 1 and an observed DCR of 60% in all evaluable patients, compared with 50% reported in the BR.21 trial for erlotinib alone in an unselected population. BR.21 was enriched with patients who were more likely to have EGFR mutations (never smokers, women, individuals of Asian descent), who were factored into the overall DCR. Subsequently, the Tarceva in Treatment of Advanced NSCLC (TITAN) study, which was not enriched in these subsets, reported a 34.5% DCR in pretreated patients who were unselected for EGFR mutation. 25 The EGFR-mutant group had much better outcome than the WT group. 25 Additional studies enrolled only patients with WT EGFR and reported DCRs for erlotinib alone in the second-line setting of 21.8% 26 and 26%. 27 Our study was powered to demonstrate an improvement in DCR over that reported in the BR.21 trial, and the 90% CI achieved (47%-71%) was within the reported 50% range but was superior to that reported in the TITAN study (34.5%). Erlotinib plus rilotumumab in the confirmed WT EGFR group achieved a DCR with a 90% CI of 46% to 73%, which was well above the best result (26%) 27 reported for erlotinib as second-line therapy in patients with WT EGFR. One-half of our patients were treated in the third-line setting, further suggesting that adding rilotumumab to erlotinib improved the DCR for patients with WT EGFR. Both patients wo had an EGFR activating mutation had stable disease. Regarding the patients with KRAS mutation, who are known to be resistant to erlotinib, 25 7 of 8 (87.5%) achieved disease control.
We identified NRG-1, a ligand for HER3, as positively correlated with improved PFS, whereas ligands with preference for EGFR (TGF-a, AREG, and HB-EGF) were either negatively correlated with PFS or had no correlation. Patients with high NRG-1 levels also had low levels of AREG and TGF-a. HER3, which is an EGFR family member that can dimerize with EGFR/HER1, can also be activated by MET 20 and may serve as a mediator of more prolonged signaling from both EGFR and MET. NSCLC tumors with high NRG-1 levels and low AREG and/or TGF-a levels may have signaling driven by HER3 activation rather than EGFR activation. These tumors may have enhanced HER family signaling resulting from EGFR/HER3 heterodimers (because HER3 lacks a kinase and needs a dimer partner to signal), and they may be more dependent on HER3 to propagate MET signaling.
The combination of erlotinib with rilotumumab could block both of these axes.
NRG-1 was associated with responses to ERBB3/ HER3-inhibitory antibodies in various tumor types 28, 29 and with resistance to cetuximab in colon cancer. 30 NRG-1 was not independently associated with survival, 29 suggesting that it is predictive of therapeutic benefit rather than prognostic. Elevated plasma TGF-a levels predicted a lack of benefit from erlotinib in the BR.21 trial, whereas AREG was not predictive but was associated with a poor prognosis. 31 Our observations are consistent with these findings. Positive AREG expression in tumor tissue was related to better survival in a retrospective study of patients with WT EGFR who received erlotinib, compared with those who had undetectable AREG expression, but plasma was not analyzed. 32 Combinations of rilotumumab with other targeted therapies or chemotherapy were examined in several tumor types and produced promising results. [33] [34] [35] [36] In metastatic gastric cancer, epirubicin/cisplatin/capecitabine chemotherapy plus rilotumumab was tested 37, 38 and led to the initiation of 2 large, phase 3 trials in patients with advanced, MET-positive gastric cancer examining rilotumumab with 2 different chemotherapy regimens. The RILOMET-1 study was stopped early based on an imbalance in deaths toward the rilotumumab plus chemotherapy arm. All statistical endpoints also were worse for patients exposed to rilotumumab, and no subgroup benefit was observed even among patients who had 11 MET expression. 39 Consequently, all sponsored trials with rilotumab in gastric cancer were terminated. 40 A separate, potent, humanized HGF monoclonal antibody, ficlatuzumab, demonstrated synergistic activity in combination with the EGFR inhibitors erlotinib and cetuximab in preclinical NSCLC models. 41 Ficlatuzumab is currently being evaluated in a phase 2 study combined with erlotinib versus erlotinib alone in previously untreated patients with EGFR-mutated NSCLC (clinicaltrials. gov identifier NCT02318368). Onartuzumab (MetMAb), the "1-armed," MET-directed monoclonal antibody, advanced to a double-blind phase 3 trial of onartuzumab plus erlotinib versus erlotinib alone in patients with previously treated, advanced NSCLC (MET-lung) but was terminated prematurely because of the lack of clinical efficacy. 42 Subsequent subset analyses demonstrated improved survival in MET-positive patients. 43 In our study, we were not able to conduct cmet protein expression or gene amplification correlative studies because of the lack of sufficient tumor tissue. A novel MET-targeting antibody that targets both ligandOriginal Article dependent and ligand-independent MET signaling, ABT-700, was well tolerated in early clinical studies and demonstrated antitumor activity in select patients who had MET-amplified tumors. 44 Many small-molecule MET inhibitors are also being evaluated in clinical trials in combination with EGFR TKIs, including cabozantinib, crizotinib, volitinib, and tivantinib. On the basis of our observation in the WT EGFR group that the DCR greatly exceeded previous reports for erlotinib alone, ongoing and future studies of MET inhibitors in combination with EGFR TKIs should further explore activity in this population in the third-line setting for patients who fail first-line and second-line chemotherapeutic and immunotherapeutic interventions. It is noteworthy that biomarker identification and patient-selection strategies to predict sensitivity to these dual-targeted studies are needed, and circulating NRG-1 should be further explored as a potential biomarker.
Conclusions
Patients with WT EGFR tumors achieved high disease control, and even patients with KRAS mutations, a factor known to confer resistance to EGFR inhibitors, appeared to produce notable disease control (with 1 response). In addition, NRG-1, a ligand for HER3, was positively correlated with improved PFS, supporting future validation studies of NRG-1 as a potential predictor of therapeutic benefit. This is in accordance with the role of HER3 as an escape mechanism through EGFR/HER3 dimerization and/or MET activation. 12 The observed DCR slightly exceeded the target based on the BR.21 trial in unselected patients; however, in the WT EGFR group, the DCR greatly exceeded previous reports for erlotinib alone. Our findings are limited by the small sample size of our study but support future testing of EGFR/MET dual-inhibition in the salvage setting, at least in the WT EGFR group.
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